44.200.169.3
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Dry Eye/OSD

FDA accepts investigational new drug application for dry eye drop

Posted on

The U.S. Food and Drug Administration (FDA) accepted an investigational new drug application for AR-15512 (Aerie Pharmaceuticals, Inc) for dry eye. AR-15512 regulates tear production and blink rate.

“The acceptance of the IND for AR-15512 marks the first clinical-stage dry eye product candidate for Aerie, another important milestone for the company. We expect to commence a Phase 2b clinical study, which will be powered as a Phase 3, later this year, with a topline readout expected in the third quarter of 2021,” said Vicente Anido, Jr., PhD, Chairman and Chief Executive Officer at Aerie, in a press release.

Read the full press release here.

-Advertisement-
Related Articles
Not All DED Patients Have Chronic Symptoms
Aug 02, 2021
Dry Eye Awareness Month: Focus on these 3 Goals
Jul 27, 2021
Systane iLux non-inferior to Lipiflow in change in meibomian gland score
Jul 25, 2021
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-